Zydus Cadila has received the final approval from the USFDA to market Tranexamic Acid Injection, 1000 mg/10 mL (100 mg/mL) Single dose Vial. Tranexamic Acid Injection belongs to the class of medications called antifibrinolytic agents.

This medication is used to prevent or reduce bleeding in patients with haemophilia undergoing tooth extraction and will be produced at the group's formulations manufacturing facility at Moraiya, in Ahmedabad.
 
The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 19.3, or 3.68%, to settle at Rs 544.25. The total volume of shares traded was 110,480 at the BSE (Wednesday).